Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

FinnGen

- PMLiVE

Sanofi/Sobi’s efanesoctocog alfa recommended by CHMP to treat haemophilia A

The rare genetic condition reduces production of factor VIII, an essential protein for blood clotting

- PMLiVE

Sanofi presents positive phase 3 results for rilzabrutinib in immune thrombocytopenia

The late-stage LUNA 3 study results will be presented at a medical congress later this year

- PMLiVE

GSK’s shingles vaccine shown to maintain high protection in long-term study

The infectious condition affects up to one in three people globally in their lifetimes

- PMLiVE

Sanofi presents promising results for investigational frexalimab in relapsing forms of MS

Approximately 85% of patients are initially diagnosed with relapsing forms of the neurological disease

- PMLiVE

Sanofi announces UK launch of inactivated rabies vaccine Verorab for all age groups

The rare neurotrophic virus is responsible for an estimated 59,000 global deaths every year

- PMLiVE

Co-funded trial shows promise for Sanofi’s diabetes drug in early Parkinson’s disease

According to WHO, the neurodegenerative disease affected more than 8.5 million people worldwide in 2019

- PMLiVE

Sanofi and Owkin expand AI collaboration to include drug positioning in immunology

The expansion builds on the companies’ strategic alliance previously announced in 2021

- PMLiVE

Gates Medical Research Institute initiates phase 3 study of tuberculosis vaccine candidate

According to WHO, the infectious disease was estimated to affect 10.6 million people in 2022

- PMLiVE

GSK’s Jemperli regimens demonstrate potential for wider endometrial cancer use

Approximately 417,000 new cases of endometrial cancer are reported globally every year

- PMLiVE

Sanofi shares promising results for amlitelimab in moderate-to-severe atopic dermatitis

Amlitelimab could potentially offer treatment for a range of other immune-mediated diseases and inflammatory disorders

- PMLiVE

GSK announces positive results for Blenrep in head-to-head multiple myeloma study

About 176,000 new cases of the blood cancer are diagnosed globally each year

- PMLiVE

Sanofi’s Xenpozyme not recommended by NICE for ultra-rare disease ASMD

An estimated 40 to 50 people in England are living with the lysosomal storage disorder

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links